New target developed to improve production of important medical radioisotope

ANSTO has made progress on a more cost-effective way to produce the medical radioisotope molybdenum-99 (Mo-99), with less enrichment of uranium-235 (U-235) and producing less waste. ANSTO supplies the Australian medical community with molybdenum-99, the precursor of technetium 99m, which is one of the most commonly used nuclear diagnostic imaging agents for the diagnosis of cancer, heart disease, organ structure and function, and supports other medical applications.